ClinicalTrials.gg
CompletedNCT07189962Updated Sep 24, 2025

A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants

A Phase 1 interventional study of SHR8554 Injection in Moderate to Severe Postoperative Pain, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Sep 2022, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 248 studies in Pain, Postoperative with a site in China — 78 open to participants now, 80 under way, 3 of them phase 3. Pain, Postoperative · China.

Enrollment
201st of 205
20 · median 132
Started
2022
with 28 others
Phase 1
6 of 248
1 open now
Registered
197th of 248
by date

Among the 248 studies in Pain, Postoperative with a site in China, this one is the 201st largest by enrollment of the 205 interventional ones that give a count, is one of 29 that started in 2022, is one of 6 in phase 1, and was the 197th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

78 of the 248 studies in Pain, Postoperative with a site in China are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Pain, Postoperative with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety and pharmacokinetic characteristics of SHR8554 injection in subjects with renal insufficiency and healthy subjects.

03

Conditions studied

  • Moderate to Severe Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written ;
  2. The estimated (eGFR) of subjects in groups must meet the corresponding standards;
  3. Male or female;
  4. with a (BMI) between 18.0 and 28.0 kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. History of allergies, known allergy to SHR8554, or any other structural analogs;
  2. Subjects with positive tests for infectious diseases;
  3. Pregnancy or lactation women, or a fertility male or female is not willing to during test;
  4. Unable to tolerate venipunctures or have a history of fainting needles and blood;
  5. Historic abuse of alcoholic beverages;
  6. Smoke ≥ 10 cigarettes per day within 3 months prior to the study;
  7. History of drug abuse;
  8. Diseases with abnormal clinical manifestations that occurred before screening or are currently occurring and need to be excluded for normal renal function group;
  9. Vital signs, physical examination, 12-lead , or laboratory examination deemed clinically significant by the investigator for normal renal function group;
  10. History of renal transplantation and/or requirement for renal dialysis treatment during the study period for severe renal function group;
  11. Urinary incontinence or anuria (e.g., \< 100 mL/day) for severe renal function group;
  12. Other reasons that the investigator consider it inappropriate to participate in the trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Normal renal function group

    Drug: SHR8554 Injection

  • Experimental
    Severe renal dysfunction group

    Drug: SHR8554 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration of SHR8554 (Cmax).

    Time frame: 0 hour to 48 hours after administration.

  2. Area under the serum concentration time curve (AUC) of SHR8554.

    Time frame: 0 hour to 48 hours after administration.

  3. Half-life (t1/2) of SHR8554.

    Time frame: 0 hour to 48 hours after administration.

  4. Clearance (CL) of SHR8554.

    Time frame: 0 hour to 48 hours after administration.

  5. Volume of distribution (Vz) of SHR8554.

    Time frame: 0 hour to 48 hours after administration.

Secondary outcomes

  1. Cumulative excretion (Ae) of SHR8554.

    Time frame: 0 hour to 48 hours after administration.

  2. Urinary excretion fraction (fe) of SHR8554.

    Time frame: 0 hour to 48 hours after administration.

  3. Renal clearance (CLr) of SHR8554.

    Time frame: 0 hour to 48 hours after administration.

  4. Plasma protein binding rate of SHR8554 in patients with renal insufficiency.

    Time frame: 0 hour to 48 hours after administration.

07

Study locations

1 site
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266003, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Apr 2023, 6 months.

Of 83 phase 1 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Sep 24, 2025
StartActual
Sep 20, 2022
Primary completionActual
Apr 13, 2023
CompletionActual
Apr 13, 2023
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07189962
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Sep 20, 2022
Primary completion
Apr 13, 2023
Completion
Apr 13, 2023
Last update
Sep 24, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR8554

Start the discussion